Armata Pharmaceuticals (ARMP) Stock Statistics & Valuation Metrics

Armata Pharmaceuticals has a market cap or net worth of $51.01M. The enterprise value is $226.53M.

Armata Pharmaceuticals has 36,183,067 shares outstanding. The number of shares has decreased by -2.65% in one year.

Armata Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Armata Pharmaceuticals is -1.69. Armata Pharmaceuticals’s PEG ratio is -0.02.

In the last 12 months, Armata Pharmaceuticals had revenue of 4.53M and earned -69.05M in profits. Earnings per share was -1.91.

In the last 12 months, operating cash flow was -37.73M and capital expenditures -4.36M, giving a free cash flow of -42.09M billion.

Armata Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Armata Pharmaceuticals upcoming earnings date is May 8, 2025, TBA Not Confirmed.

Armata Pharmaceuticals as a current ratio of 1.16, with Debt / Equity ratio of -275.29%

In the past 12 months, Armata Pharmaceuticals has paid 0.00 in taxes.

Armata Pharmaceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Armata Pharmaceuticals has $17.14M in cash and marketable securities with $120.37M in debt, giving a net cash position of $123.19M billion.

Gross margin is 62.91%, with operating margin of -902.85%, and net profit margin of -1524.51%.

The average price target for Armata Pharmaceuticals is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy